Overview

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Status:
RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Phase:
PHASE2
Details
Lead Sponsor:
Eli Lilly and Company